| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Colonic Neoplasms | 5 | 2018 | 295 | 0.65 | Why? |
| Weight Reduction Programs | 4 | 2018 | 87 | 0.63 | Why? |
| Cancer Survivors | 6 | 2018 | 588 | 0.62 | Why? |
| Reminder Systems | 3 | 2019 | 104 | 0.53 | Why? |
| Motivation | 5 | 2018 | 1640 | 0.41 | Why? |
| Minority Groups | 2 | 2020 | 1631 | 0.41 | Why? |
| Urban Population | 1 | 2020 | 2000 | 0.40 | Why? |
| Medication Adherence | 5 | 2019 | 1270 | 0.39 | Why? |
| Exercise Therapy | 4 | 2018 | 976 | 0.37 | Why? |
| Breast Cancer Lymphedema | 2 | 2018 | 18 | 0.37 | Why? |
| Poverty | 1 | 2020 | 2302 | 0.36 | Why? |
| Neoplastic Cells, Circulating | 2 | 2018 | 68 | 0.34 | Why? |
| Patient Care Bundles | 2 | 2018 | 137 | 0.30 | Why? |
| Adrenergic beta-Antagonists | 2 | 2020 | 465 | 0.29 | Why? |
| Information Dissemination | 1 | 2020 | 2986 | 0.27 | Why? |
| Reimbursement, Incentive | 3 | 2019 | 70 | 0.27 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2021 | 10649 | 0.25 | Why? |
| Biomarkers, Tumor | 4 | 2018 | 1314 | 0.23 | Why? |
| Insurance Claim Review | 2 | 2019 | 108 | 0.23 | Why? |
| Brain Diseases, Metabolic | 1 | 2021 | 24 | 0.22 | Why? |
| Exercise | 6 | 2018 | 6771 | 0.22 | Why? |
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 45 | 0.21 | Why? |
| Text Messaging | 3 | 2019 | 389 | 0.20 | Why? |
| Drug Packaging | 1 | 2019 | 33 | 0.20 | Why? |
| Sentinel Lymph Node | 1 | 2019 | 35 | 0.20 | Why? |
| Drug Prescriptions | 2 | 2019 | 1062 | 0.19 | Why? |
| Physician Incentive Plans | 1 | 2018 | 18 | 0.19 | Why? |
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 98 | 0.19 | Why? |
| Dental Caries | 1 | 2020 | 163 | 0.18 | Why? |
| Triple Negative Breast Neoplasms | 1 | 2018 | 92 | 0.18 | Why? |
| Arthroplasty, Replacement | 1 | 2018 | 47 | 0.18 | Why? |
| Health Planning Support | 1 | 2016 | 2 | 0.17 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2019 | 1510 | 0.17 | Why? |
| Tumor Burden | 1 | 2018 | 369 | 0.17 | Why? |
| Prescription Drug Misuse | 1 | 2017 | 54 | 0.17 | Why? |
| Lymphedema | 1 | 2017 | 44 | 0.17 | Why? |
| Feedback | 1 | 2019 | 317 | 0.17 | Why? |
| Reward | 1 | 2018 | 146 | 0.16 | Why? |
| Body Composition | 2 | 2017 | 414 | 0.16 | Why? |
| Cost Sharing | 1 | 2016 | 39 | 0.16 | Why? |
| Medicare Part C | 1 | 2017 | 49 | 0.16 | Why? |
| Calcium Channel Blockers | 1 | 2020 | 367 | 0.16 | Why? |
| Upper Extremity | 1 | 2018 | 193 | 0.15 | Why? |
| Hippocampus | 1 | 2018 | 237 | 0.15 | Why? |
| Breast Neoplasms | 3 | 2019 | 3633 | 0.15 | Why? |
| Small Cell Lung Carcinoma | 1 | 2017 | 133 | 0.15 | Why? |
| Reimbursement Mechanisms | 1 | 2018 | 243 | 0.15 | Why? |
| Weight Loss | 2 | 2018 | 826 | 0.15 | Why? |
| Hypolipidemic Agents | 1 | 2017 | 208 | 0.14 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.14 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.14 | Why? |
| Lymphoma, Non-Hodgkin | 1 | 2017 | 403 | 0.13 | Why? |
| Pharmacies | 1 | 2019 | 356 | 0.13 | Why? |
| Behavior Therapy | 1 | 2016 | 235 | 0.13 | Why? |
| Datasets as Topic | 1 | 2020 | 1404 | 0.13 | Why? |
| Cholesterol, LDL | 1 | 2017 | 499 | 0.13 | Why? |
| Nomograms | 1 | 2019 | 790 | 0.12 | Why? |
| Cooperative Behavior | 1 | 2020 | 1216 | 0.12 | Why? |
| Patient Selection | 2 | 2017 | 4560 | 0.12 | Why? |
| Brain Diseases | 2 | 2021 | 1463 | 0.12 | Why? |
| Myocardial Infarction | 2 | 2019 | 3361 | 0.12 | Why? |
| Arthroplasty, Replacement, Knee | 1 | 2017 | 363 | 0.11 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2017 | 403 | 0.11 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.11 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.11 | Why? |
| Tumor Suppressor Protein p53 | 2 | 2018 | 310 | 0.11 | Why? |
| Medicare | 4 | 2019 | 1048 | 0.10 | Why? |
| Electronic Nicotine Delivery Systems | 1 | 2018 | 561 | 0.10 | Why? |
| Smoking Cessation | 1 | 2018 | 826 | 0.10 | Why? |
| Obesity | 3 | 2017 | 7388 | 0.10 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.09 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Hypertension | 3 | 2020 | 8895 | 0.09 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.09 | Why? |
| Female | 36 | 2021 | 380317 | 0.09 | Why? |
| Middle Aged | 29 | 2021 | 270681 | 0.09 | Why? |
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1 | 2006 | 1 | 0.09 | Why? |
| Schizophrenia | 1 | 2018 | 1018 | 0.09 | Why? |
| Psychotic Disorders | 1 | 2018 | 924 | 0.09 | Why? |
| Tracheostomy | 1 | 2021 | 1963 | 0.09 | Why? |
| Evolution, Molecular | 1 | 2021 | 3691 | 0.09 | Why? |
| Arylsulfotransferase | 1 | 2006 | 2 | 0.09 | Why? |
| Quinones | 1 | 2006 | 43 | 0.08 | Why? |
| Body Image | 1 | 2008 | 96 | 0.08 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.08 | Why? |
| Quality of Life | 4 | 2021 | 9820 | 0.08 | Why? |
| New York City | 4 | 2021 | 7432 | 0.08 | Why? |
| Humans | 46 | 2021 | 930598 | 0.08 | Why? |
| Polycyclic Aromatic Hydrocarbons | 1 | 2006 | 30 | 0.08 | Why? |
| Arthritis, Rheumatoid | 1 | 2020 | 2043 | 0.08 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.08 | Why? |
| Estrogen Replacement Therapy | 1 | 2006 | 50 | 0.08 | Why? |
| Social Support | 2 | 2018 | 3183 | 0.08 | Why? |
| Health Promotion | 2 | 2018 | 2020 | 0.08 | Why? |
| United States | 9 | 2020 | 46150 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2021 | 253789 | 0.08 | Why? |
| Chloroquine | 1 | 2021 | 3152 | 0.08 | Why? |
| Aged | 22 | 2021 | 215776 | 0.08 | Why? |
| Brain Ischemia | 1 | 2021 | 2813 | 0.08 | Why? |
| Neoplasm Recurrence, Local | 3 | 2017 | 1063 | 0.08 | Why? |
| Biological Products | 1 | 2020 | 2331 | 0.07 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.07 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.07 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.07 | Why? |
| Adult | 23 | 2021 | 244371 | 0.07 | Why? |
| Male | 28 | 2021 | 367725 | 0.07 | Why? |
| Endometrial Neoplasms | 1 | 2006 | 120 | 0.07 | Why? |
| Employment | 1 | 2016 | 1754 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Diabetes Mellitus | 2 | 2018 | 8207 | 0.07 | Why? |
| Infant Formula | 1 | 2005 | 64 | 0.07 | Why? |
| Hospital Costs | 2 | 2018 | 274 | 0.07 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.07 | Why? |
| Attitude to Health | 1 | 2017 | 2002 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.06 | Why? |
| Single-Blind Method | 2 | 2018 | 1283 | 0.06 | Why? |
| Estrogens | 1 | 2006 | 252 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| African Americans | 1 | 2017 | 3363 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2020 | 4092 | 0.06 | Why? |
| Primary Health Care | 2 | 2018 | 4839 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Activities of Daily Living | 2 | 2021 | 1530 | 0.05 | Why? |
| New York | 2 | 2020 | 2488 | 0.05 | Why? |
| Reactive Oxygen Species | 1 | 2006 | 1136 | 0.05 | Why? |
| Odds Ratio | 3 | 2021 | 5861 | 0.05 | Why? |
| Lung Neoplasms | 1 | 2017 | 3228 | 0.05 | Why? |
| Neurotoxicity Syndromes | 1 | 2020 | 124 | 0.05 | Why? |
| Dilatation | 1 | 2021 | 181 | 0.05 | Why? |
| Weight Gain | 1 | 2005 | 552 | 0.05 | Why? |
| Health Behavior | 1 | 2018 | 4449 | 0.05 | Why? |
| Spinal Cord Diseases | 1 | 2020 | 141 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Body Weights and Measures | 1 | 2018 | 50 | 0.05 | Why? |
| Patient Readmission | 2 | 2019 | 1543 | 0.05 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.04 | Why? |
| Cell Count | 1 | 2018 | 228 | 0.04 | Why? |
| Hawaii | 1 | 2018 | 163 | 0.04 | Why? |
| Amine Oxidase (Copper-Containing) | 1 | 2017 | 13 | 0.04 | Why? |
| Stroke | 1 | 2021 | 8839 | 0.04 | Why? |
| Diet, Reducing | 1 | 2017 | 38 | 0.04 | Why? |
| Pilot Projects | 2 | 2020 | 5182 | 0.04 | Why? |
| Atrophy | 1 | 2018 | 192 | 0.04 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.04 | Why? |
| Episode of Care | 1 | 2017 | 27 | 0.04 | Why? |
| Treatment Outcome | 6 | 2020 | 51732 | 0.04 | Why? |
| Antihypertensive Agents | 2 | 2020 | 1962 | 0.04 | Why? |
| Neoplasm Invasiveness | 1 | 2019 | 582 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Organ Size | 1 | 2018 | 384 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2019 | 537 | 0.04 | Why? |
| Asian Americans | 1 | 2020 | 387 | 0.04 | Why? |
| Blood Pressure | 2 | 2019 | 2198 | 0.04 | Why? |
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 189 | 0.04 | Why? |
| Oral Health | 1 | 2020 | 401 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Random Allocation | 1 | 2018 | 773 | 0.04 | Why? |
| Delivery of Health Care | 2 | 2019 | 15909 | 0.04 | Why? |
| Survivors | 1 | 2008 | 2619 | 0.04 | Why? |
| Community Health Workers | 1 | 2020 | 468 | 0.04 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.04 | Why? |
| Pregnancy Complications, Infectious | 1 | 2021 | 11559 | 0.04 | Why? |
| Intra-Abdominal Fat | 1 | 2017 | 227 | 0.04 | Why? |
| Occupational Health Services | 1 | 2018 | 219 | 0.04 | Why? |
| Histones | 1 | 2017 | 371 | 0.03 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.03 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.03 | Why? |
| Resistance Training | 1 | 2017 | 273 | 0.03 | Why? |
| Cell Adhesion Molecules | 1 | 2017 | 472 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2020 | 1475 | 0.03 | Why? |
| Patient Participation | 1 | 2021 | 829 | 0.03 | Why? |
| Medication Therapy Management | 1 | 2017 | 312 | 0.03 | Why? |
| Medicaid | 1 | 2018 | 492 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.03 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.03 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.03 | Why? |
| Insulin Resistance | 1 | 2017 | 669 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.03 | Why? |
| Propensity Score | 1 | 2020 | 2690 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.03 | Why? |
| Neoplasm Staging | 1 | 2018 | 1999 | 0.03 | Why? |
| Overweight | 1 | 2017 | 916 | 0.03 | Why? |
| Population Health | 1 | 2018 | 504 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Interpersonal Relations | 1 | 2018 | 926 | 0.03 | Why? |
| Risk Reduction Behavior | 1 | 2017 | 946 | 0.02 | Why? |
| Socioeconomic Factors | 2 | 2018 | 8495 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2016 | 1316 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Interviews as Topic | 1 | 2017 | 1952 | 0.02 | Why? |
| Mutagenicity Tests | 1 | 2006 | 13 | 0.02 | Why? |
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 5 | 0.02 | Why? |
| Aftercare | 1 | 2017 | 1637 | 0.02 | Why? |
| Cytochrome P-450 CYP1B1 | 1 | 2006 | 10 | 0.02 | Why? |
| Cytochrome P-450 CYP1A2 | 1 | 2006 | 25 | 0.02 | Why? |
| International Cooperation | 1 | 2021 | 3436 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Cytochrome P-450 CYP1A1 | 1 | 2006 | 39 | 0.02 | Why? |
| Glucuronosyltransferase | 1 | 2006 | 24 | 0.02 | Why? |
| Mutagens | 1 | 2006 | 38 | 0.02 | Why? |
| Sulfotransferases | 1 | 2006 | 25 | 0.02 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1573 | 0.02 | Why? |
| Fatigue | 1 | 2018 | 2479 | 0.02 | Why? |
| Physician-Patient Relations | 1 | 2017 | 1266 | 0.02 | Why? |
| Research Design | 2 | 2017 | 5830 | 0.02 | Why? |
| Cytochrome P-450 CYP3A | 1 | 2006 | 88 | 0.02 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.02 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.02 | Why? |
| Progesterone | 1 | 2006 | 106 | 0.02 | Why? |
| Cytochrome P-450 Enzyme System | 1 | 2006 | 144 | 0.02 | Why? |
| Genes, Reporter | 1 | 2006 | 472 | 0.02 | Why? |
| Philadelphia | 1 | 2006 | 454 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Quality of Health Care | 1 | 2017 | 1948 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Saccharomyces cerevisiae | 1 | 2006 | 339 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.02 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Young Adult | 3 | 2020 | 93724 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2019 | 9537 | 0.02 | Why? |
| Prognosis | 2 | 2017 | 32490 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Body Mass Index | 2 | 2008 | 4306 | 0.02 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.02 | Why? |
| Sex Factors | 1 | 2020 | 11014 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Gene Frequency | 1 | 2006 | 1210 | 0.01 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.01 | Why? |
| Molecular Structure | 1 | 2006 | 1539 | 0.01 | Why? |
| Logistic Models | 2 | 2006 | 9089 | 0.01 | Why? |
| Internet | 1 | 2018 | 6204 | 0.01 | Why? |
| Neoplasms | 1 | 2008 | 17251 | 0.01 | Why? |
| Polymorphism, Genetic | 1 | 2006 | 1074 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.01 | Why? |
| Body Weight | 1 | 2005 | 1074 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.01 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Child | 2 | 2021 | 70012 | 0.01 | Why? |
| Genotype | 1 | 2006 | 4697 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2006 | 6740 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2018 | 48226 | 0.01 | Why? |
| Case-Control Studies | 1 | 2006 | 17671 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |
| Infant, Newborn | 1 | 2005 | 23105 | 0.00 | Why? |